Imugene Limited - ROE
IUGNF
Price:
$0.095
Market Cap:
$47.82M
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another ...[Read more]
Industry
Biotechnology
IPO Date
2019-07-05
Stock Exchange
OTC
Ticker
IUGNF
PE Ratio
[-0.59]
ROE
[-134.65%]
Current Ratio
[1.78]
Dividend Yield
[0%]
Enterprise Value
[38.71M]
Dividend History
The ROE as of June 2026 (TTM) for Imugene Limited (IUGNF) is -134.65%
According to Imugene Limited’s latest financial reports and current stock price. The company's current ROE is -134.65%. This represents a change of 91.58% compared to the average of -70.28% of the last 4 quarters.
Imugene Limited (IUGNF) Historical ROE (quarterly & annually)
How has IUGNF ROE performed in the past?
The mean historical ROE of Imugene Limited over the last ten years is -48.38%. The current -134.65% ROE has changed 178.33% with respect to the historical average. Over the past ten years (40 quarters), IUGNF's ROE was at its highest in in the June 2009 quarter at 6.10%. The ROE was at its lowest in in the June 2012 quarter at -145.98%.
Average
-48.38%
Median
-27.84%
Minimum
-153.27%
Maximum
-17.57%
Imugene Limited (IUGNF) ROE by Quarter and Year
Discovering the peaks and valleys of Imugene Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 533.05%
Maximum Annual ROE = -17.57%
Minimum Annual Increase = -38.32%
Minimum Annual ROE = -153.27%
| Year | ROE | Change |
|---|---|---|
| 2025 | -153.27% | 21.09% |
| 2024 | -126.58% | 533.05% |
| 2023 | -19.99% | -26.76% |
| 2022 | -27.30% | -3.81% |
| 2021 | -28.38% | 61.55% |
| 2020 | -17.57% | -38.32% |
| 2019 | -28.49% | 12.06% |
| 2018 | -25.42% | 15.54% |
| 2017 | -22.00% | -36.71% |
| 2016 | -34.76% | 10.11% |
Imugene Limited (IUGNF) Average ROE
How has IUGNF ROE performed in the past?
The current ROE of Imugene Limited (IUGNF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-99.95%
5-year avg
-71.11%
10-year avg
-48.38%
Imugene Limited (IUGNF) ROE vs. Peers
How is IUGNF’s ROE compared to its peers?
Imugene Limited’s ROE is greater than Alterity Therapeutics Limited (-30.19%), greater than Starpharma Holdings Limited (-15.96%), greater than Satellos Bioscience Inc. (-51.42%), greater than Nicox S.A. (-51.16%), greater than BioStem Technologies, Inc. (-47.03%), greater than Poolbeg Pharma PLC (-55.47%), less than VitaSpring Biomedical Co. Ltd. (9.39%), less than H-Source Holdings Ltd. (197.97%), greater than Kintor Pharmaceutical Limited (-98.57%), greater than Calliditas Therapeutics Ab (-84.68%),
| Company | ROE | Market cap |
|---|---|---|
| -30.19% | $11.96M | |
| -15.96% | $210.46M | |
| -51.42% | $96.62M | |
| -51.16% | $30.94M | |
| -47.03% | $67.94M | |
| -55.47% | $64.80M | |
| 9.39% | $2.30M | |
| 197.97% | $1.18K | |
| -98.57% | $160.37M | |
| -84.68% | $13.47M |
Build a custom stock screener for Imugene Limited (IUGNF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Imugene Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Imugene Limited (IUGNF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Imugene Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Imugene Limited's ROE?
How is the ROE calculated for Imugene Limited (IUGNF)?
What is the highest ROE for Imugene Limited (IUGNF)?
What is the 3-year average ROE for Imugene Limited (IUGNF)?
What is the 5-year average ROE for Imugene Limited (IUGNF)?
How does the current ROE for Imugene Limited (IUGNF) compare to its historical average?